Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 16/20 | 0.40 |
| ▸ | RANBP1 | P43487 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17788720 | 1.00 | XPO1 (0.40) | XPO1RANBP1KCNH2JMJD6ELANE | |
| SCHEMBL17788721 | 1.00 | XPO1 (0.40) | XPO1RANBP1KCNH2JMJD6ELANE | |
| SCHEMBL19261690 | 0.91 | XPO1 (0.50) | XPO1RANBP1KCNH2 | |
| SCHEMBL17788862 | 0.88 | TDP1 (0.41) | XPO1RANBP1KCNH2ELANEKMT2A | |
| SCHEMBL26326438 | 0.87 | XPO1 (0.51) | XPO1RANBP1KCNH2 | |
| SCHEMBL17788876 | 0.87 | XPO1 (0.51) | XPO1RANBP1KCNH2 | |
| SCHEMBL16361561 | 0.86 | XPO1 (0.55) | XPO1RANBP1KCNH2 | |
| SCHEMBL17790550 | 0.86 | XPO1 (0.55) | XPO1RANBP1KCNH2 | |
| SCHEMBL17788872 | 0.84 | XPO1 (0.41) | XPO1RANBP1KCNH2 | |
| SCHEMBL17788864 | 0.83 | XPO1 (0.53) | XPO1RANBP1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155317-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2018-06-07 | — | — | US | disclosed |
| US-9738624-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160152596-A1 | Nuclear Transport Modulators and Uses Thereof | Karyopharm Therapeutics Inc. (US) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155317-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | XPO1 1/4885RANBP1 159/4885KCNH2 4379/4885 |
| US-20160152596-A1 | Nuclear Transport Modulators and Uses Thereof | XPO5, XPO1, XPOT | XPO1 2/4885RANBP1 144/4885KCNH2 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.